Status:
COMPLETED
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Staphylococcus Aureus Bacteraemia
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S. aureus b...
Detailed Description
Single center randomized controlled trial of direct thrombin inhibitors versus standard enoxaparin. * Feasibility: proportion of patients eligible for randomization; clinically attained concentration...
Eligibility Criteria
Inclusion
- Positive blood culture for staphylococcus aureus
- Symptoms or signs of infection
- Indication for thromboprophylaxis
Exclusion
- Contraindication for thromboprophylaxis
- Significant active bleeding or risk of excessive bleeding
- Heparin-induced thrombocytopenia
- Severe liver and kidney disease
- Pregnancy and lactation.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01911624
Start Date
January 1 2013
End Date
July 1 2016
Last Update
July 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KUleuven/UZ Gasthuisberg
Leuven, Belgium, 3000